Screening and Identification of Antibodies with Cross-binding Activity to Human and Mouse IL-1R3

doi:10.13523/j.cb.2305033

China Biotechnology

2024, Vol. 44

Issue (2/3): 14-24 DOI: 10.13523/j.cb.2305033

Screening and Identification of Antibodies with Cross-binding Activity to Human and Mouse IL-1R3

QIN Hui^1,²,YU Xinrui^2,³,LIU Jiao^1,²,Gulisaina Qiaerxie^2,⁴,CUI Jingmin^2,⁴,WANG Xi²,DU Peng^2,^*(

),ZHOU Chunyang^1,^*(

)

1 School of Pharmacy, North Sichuan Medical College, Institute of Pharmaceutical Research,North Sichuan Medical College, Nanchong 637000, China
2 Institute of Biotechnology, Academy of Military Medical Science, Academy of Military Science, Beijing 100071, China
3 School of Basic Medical Sciences and Life Sciences, Hainan Medical University, Haikou 571158, China
4 School of Medical Instrumentation, Shenyang Pharmaceutical University, Benxi 117004, China

Download:

HTML

PDF(2265KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract

Objective: Interleukin-1 receptor accessory protein (IL-1R3) is a potential new target for inflammation regulation. The aim of this study is to obtain anti-IL-1R3 antibodies with cross-binding activity to human and mouse IL-1R3 and to lay the foundation for the new drug development and pharmacodynamic mechanism research of a novel inflammation intervention strategy. Methods: Based on the sequence and structure alignment of human and mouse IL-1R3, a phage-displayed human single-chain (scFv) antibody library was challenged by alternately coating immune-tubes with human or mouse IL-1R3. The variable region genes of the resulting antibodies were cloned into eukaryotic expression vectors to prepare antibodies. The binding activities of the candidate antibodies were determined by ELISA and SPR and their functional activities were evaluated by cell assay. A strategy of re-pairing the light and heavy chains of these antibodies was then followed to obtain new antibodies with improved properties. Results: Five antibodies with cross-binding activity to human and mouse IL-1R3 were identified, four of which showed comparable affinity to both human and mouse IL-1R3, approximately 10^-7 mol/L. Two candidate antibodies with favorable solubility effectively blocked IL-1R3-mediated activities in the ex vivo functional assay. A new antibody with re-paired light and heavy chains showed improved binding activity and apparently increased solubility. Conclusions: By introducing antibodies AET1907 and 4H6L with comparable human-mouse IL-1R3 cross-binding activity, this study has laid the groundwork for further investigation.

Key words： IL-1R3 Antibody Phage-displayed Antibody library Cross-binding activity Solubility

Received: 25 May 2023 Published: 03 April 2024

ZTFLH:

Q342+.4

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Hui QIN
	Xinrui YU
	Jiao LIU
	Qiaerxie Gulisaina
	Jingmin CUI
	Xi WANG
	Peng DU
	Chunyang ZHOU

Cite this article:

QIN Hui, YU Xinrui, LIU Jiao, Gulisaina Qiaerxie, CUI Jingmin, WANG Xi, DU Peng, ZHOU Chunyang. Screening and Identification of Antibodies with Cross-binding Activity to Human and Mouse IL-1R3. China Biotechnology, 2024, 44(2/3): 14-24.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.2305033 OR https://manu60.magtech.com.cn/biotech/Y2024/V44/I2/3/14

Fig.1 Sequence and structure alignment of human IL-1R3 (huIL-1R3) and mouse IL-1R3 (moIL-1R3) A: Sequence alignment of human and mouse IL-1R3,the amino acid similarity was shaded differently B: Structure alignment of extracellular domain D2 (ECD-D2, 120-215AA as shown in A) of human and mouse IL-1R3, which covers its most ligand recognition region

Table 1 Selection of anti-IL-1R3 scFv antibodies

Fig.2 Identification of phage-displayed antibodies selected from the library and binding specificity of enriched antibodies A: Recombinant human IL-1R3 with histidine tag (huIL-1R3-His) and negative antigen controls (BSA and KDR-His) were parallelly coated in an ELISA assay and the optical density (OD) measured B:The binding specificity was approximated using ELISA. The coating amount of human IL-1R3 (huIL-1R3-His) and mouse IL-1R3 (moIL-1R3-His) was 50 ng/well, while that of other antigens was 100 ng/well. The concentration of antibody was 10 μg/mL

Fig.3 The binding activity of antibodies to human IL-1R3 (A) and mouse IL-1R3 (B) Human or mouse IL-1R3 were coated in 96-well microtiter plates at 100 ng/well and serially di-luted antibodies were detected by ELISA assay

Fig.4 Representative sensorgrams of antibodies in SPR assays The antibodies were immobilized separately on the sensor chip surface, and human and mouse IL-1R3-His at serially diluted (37.5-600 nmol/L) concentrations were passed over the chip. The fitting curves (thin black lines) were derived from analysis using the 1∶1 binding mode. Equilibrium disassociation constants (K_D) were calculated according to fitting curves. ^* The value is derived from the steady-state calculation (1∶1 binding) for a better fit

Table 2 Affinity constant of antibodies interacting with human and mouse IL-1R3

Fig.5 Antibodies effectively blocked IL-1R3-mediated functional activity A,B: Inhibitory effects of AET1907(A) and AET1912(B) on IL-1β-stimulated IL-6 secretion of human lung epithelial cell line (A549) C,D: Inhibitory effects of AET1907(C) and AET1912(D) on IL-36α-stimulated IL-8 secretion of human keratinocyte cell line (HaCaT). Data were processed using GraphPad Prism Software, and data shown are mean ± SD from one representative experiment. ^*** P<0.001, ^** P<0.01, ^* P<0.05 (t-test)

Fig.6 Variable region sequence alignment of the light chain and heavy chain of antibodies (A) and the affinity of 4H6L (B) A: The amino acid similarity was shaded differently B: The concentrations of re-paired antibody 4H6L are 600 nmol/L, 300 nmol/L, 150 nmol/L, 75 nmol/L and 37.5 nmol/L. The K_D value is calculated according to fitting curves using the 1∶1 binding mode


[1]	Medzhitov R. The spectrum of inflammatory responses. Science, 2021, 374(6571): 1070-1075. doi: 10.1126/science.abi5200 pmid: 34822279

[2]	Fajgenbaum D C, June C H. Cytokine storm. The New England Journal of Medicine, 2020, 383(23): 2255-2273. doi: 10.1056/NEJMra2026131 pmid: 33264547

[3]	Mantovani A, Garlanda C. Humoral innate immunity and acute-phase proteins. The New England Journal of Medicine, 2023, 388(5): 439-452. doi: 10.1056/NEJMra2206346 pmid: 36724330

[4]	Palomo J, Dietrich D, Martin P, et al. The interleukin (IL)-1 cytokine family: balance between agonists and antagonists in inflammatory diseases. Cytokine, 2015, 76(1): 25-37. doi: 10.1016/j.cyto.2015.06.017

[5]	Mantovani A, Dinarello C A, Molgora M, et al. Interleukin-1 and related cytokines in the regulation of inflammation and immunity. Immunity, 2019, 50(4): 778-795. doi: S1074-7613(19)30129-3 pmid: 30995499

[6]	Barkas F, Christaki E, Liberopoulos E, et al. Anakinra in COVID-19: a step closer to the cure. European Journal of Internal Medicine, 2022, 96: 113-114. doi: 10.1016/j.ejim.2021.11.005

[7]	Makaremi S, Asgarzadeh A, Kianfar H, et al. The role of IL-1 family of cytokines and receptors in pathogenesis of COVID-19. Inflammation Research, 2022, 71(7): 923-947. doi: 10.1007/s00011-022-01596-w

[8]	Angus D C, van der Poll T. Severe sepsis and septic shock. New England Journal of Medicine, 2013, 369(9): 840-851. doi: 10.1056/NEJMra1208623

[9]	Burkovskiy I, Sardinha J, Zhou J, et al. Cytokine release in sepsis. Advances in Bioscience and Biotechnology, 2013, 4(9): 860-865. doi: 10.4236/abb.2013.49114

[10]	Heffernan I M, McGeary J E, Chung C S, et al. Unmasking unique immune altering aspects of the microbiome as a tool to correct sepsis-induced immune dysfunction. Surgical Infections, 2021, 22(4): 400-408. doi: 10.1089/sur.2020.233

[11]	Yang M, Wang Y W, Zhang Y H, et al. Role of interleukin-33 in Staphylococcus epidermidis-induced septicemia. Frontiers in Immunology, 2020, 11: 534099. doi: 10.3389/fimmu.2020.534099

[12]	Nascimento D C, Melo P H, Piñeros A R, et al. IL-33 contributes to sepsis-induced long-term immunosuppression by expanding the regulatory T cell population. Nature Communications, 2017, 8: 14919. doi: 10.1038/ncomms14919 pmid: 28374774

[13]	Xu H, Turnquist H R, Hoffman R, et al. Role of the IL-33-ST 2 axis in sepsis. Military Medical Research, 2017, 4: 3. doi: 10.1186/s40779-017-0115-8

[14]	Buhl A L, Wenzel J. Interleukin-36 in infectious and inflammatory skin diseases. Frontiers in Immunology, 2019, 10: 1162. doi: 10.3389/fimmu.2019.01162

[15]	Nanjo Y, Newstead M W, Aoyagi T, et al. Overlapping roles for interleukin-36 cytokines in protective host defense against murine Legionella pneumophila pneumonia. Infection and Immunity, 2019, 87(1): e00583-e00518.

[16]	Aoyagi T, Newstead M W, Zeng X Y, et al. Interleukin-36γ and IL-36 receptor signaling mediate impaired host immunity and lung injury in cytotoxic Pseudomonas aeruginosa pulmonary infection: role of prostaglandin E2. PLoS Pathogens, 2017, 13(11): e1006737.

[17]	Aoyagi T, Newstead M W, Zeng X, et al. IL-36 receptor deletion attenuates lung injury and decreases mortality in murine influenza pneumonia. Mucosal Immunology, 2017, 10(4): 1043-1055. doi: 10.1038/mi.2016.107 pmid: 27966554

[18]	Højen J F, Kristensen M L V, McKee A S, et al. IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease. Nature Immunology, 2019, 20: 1138-1149. doi: 10.1038/s41590-019-0467-1 pmid: 31427775

[19]	Boraschi D, Italiani P, Weil S, et al. The family of the interleukin-1 receptors. Immunological Reviews, 2018, 281(1): 197-232. doi: 10.1111/imr.12606 pmid: 29248002

[20]	Jensen L E. Interleukin-36 cytokines may overcome microbial immune evasion strategies that inhibit interleukin-1 family signaling. Science Signaling, 2017, 10(492): eaan3589.

[21]	Fields J K, Kihn K, Birkedal G S, et al. Molecular basis of selective cytokine signaling inhibition by antibodies targeting a shared receptor. Frontiers in Immunology, 2021, 12: 779100. doi: 10.3389/fimmu.2021.779100

[22]	Rydberg Millrud C, Deronic A, Grönberg C, et al. Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy. Cancer Immunology, Immunotherapy, 2023, 72(3): 667-678. doi: 10.1007/s00262-022-03277-3

[23]	Robbrecht D, Jungels C, Sorensen M M, et al. First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours. British Journal of Cancer, 2022, 126: 1010-1017. doi: 10.1038/s41416-021-01657-7

[1]	GUO Rao-qing, HUANG Jia-wen, ZHANG Li-gang, ZHAO Wen-li, GU Jiang-tao, DENG-Ning. Preparation of a Fully Human Anti-PD-L1 Disulfide-stabilized Diabody with High Affinity and Stability[J]. China Biotechnology, 2023, 43(6): 20-30.

[2]	LIN Peng, QIAN Jing, FENG Qiang, LEI Jing, JIANG Ya, YANG Ju-lun. Production of Single-chain Fragment Variable and Its Application in Tumor Diagnosis and Treatment[J]. China Biotechnology, 2023, 43(6): 76-86.

[3]	JIN Mei-qin, SHANG Cheng-zhang, SHEN Yue-lei. Development and Anti-tumor Study of Bispecific Antibody Drug Conjugate Targeting TPBG and EGFR[J]. China Biotechnology, 2023, 43(5): 11-23.

[4]	SUN Bai-he, WU Yue, ZHAO Rui, LOU Yu-xin, LI Wan-ting, LI Yan-fei, MA Lin-lin. Research Progress of Therapeutic Nanobodies with Different Expression Systems[J]. China Biotechnology, 2023, 43(11): 43-55.

[5]	LIU Yu-ping, DENG Chang-ping, MA Xing-yuan, LIU Qiu-li, BAO Wen, ZHENG Wen-yun. *Preparation and in vitro* Activity of Anti-EpCAM Immunotoxin**[J]. China Biotechnology, 2023, 43(10): 10-19.

[6]	SHEN Yan, YAO Bin-yan, YANG Ruo-nan, KANG Wen-bin, LIN Hai-ying. Preparation and Application of Immunoassay Signal Amplification Antibody Conjugates[J]. China Biotechnology, 2023, 43(1): 42-49.

[7]	Kun WANG,Fu-yun ZHAO,Yun-fei XU,Xiao-feng YUAN,Wei-chun ZHAO. *Preparation of Monoclonal Antibody Against Fusarium solani* and Development of Its Colloidal Gold Immunochromatographic Strip**[J]. China Biotechnology, 2022, 42(7): 54-61.

[8]	ZHANG Xin-di,FAN Chang-wei,SONG Xiao-qing,XU Cui-yun,HUANG Feng-jie. Root Cause and Prevention of Monoclonal Antibody Disulfide Bonds Reduction During Biopharmaceutical Manufacturing Process[J]. China Biotechnology, 2022, 42(6): 66-75.

[9]	ZENG Hong-ye,NING Wen-jing,LUO Wen-xin. Advances in the Study of Antibody Composition and Targets of ADC Drugs[J]. China Biotechnology, 2022, 42(5): 69-80.

[10]	CHEN Yang, LIU Tong, ZHANG Jia-qi, LIAO Hua-xin, LIN Yue-zhi, WANG Xiao-jun, WANG Ya-yu. Screening of Monoclonal Antibodies Targeting the Equine IgG1 Based on Single B Cell Antibodies Gene Amplification Technology[J]. China Biotechnology, 2022, 42(4): 17-23.

[11]	LI Kai-tong, LIU Jin-qing, CAI Wang-wei, XIAO Man, SHEN Bei-fen, WANG Jing, FENG Jian-nan. Advances of Therapeutic Monoclonal Antibodies Targeting Human Interleukin-6 Protein[J]. China Biotechnology, 2022, 42(4): 58-67.

[12]	Qian LI,Xiao-ying LIANG,Guo-zhu LI,Qing-quan HE,Huang-hong TAN,Zi-chen WANG,Guang-liu XU,jing LI,Meng-ni FAN,Dan XU. Insight into the Purification Strategies for Removing the Byproducts of Bispecific Antibodies[J]. China Biotechnology, 2022, 42(10): 60-69.

[13]	CHEN Xiu-yue,ZHOU Wen-feng,HE Qing,SU Bing,ZOU Ya-wen. Preparation, Purification and Identification of Bacteriophage Qβ Virus-like Particles[J]. China Biotechnology, 2021, 41(7): 42-49.

[14]	XU Ye-chun,LIU Hong,LI Jian-feng,SHEN Jing-shan,JIANG Hua-liang. Recent Progress in Drug Development against COVID-19[J]. China Biotechnology, 2021, 41(6): 111-118.

[15]	CHEN Wen-jie,MIAO Xian-feng. Domestic Research and Development Status of Antibody-drug Conjugates and Strategic Layout of Key Enterprises[J]. China Biotechnology, 2021, 41(6): 105-110.

Viewed

Full text

Abstract

Cited

Shared

Discussed